Bacterial ligands in the rehabilitation of healthcare workers after COVID-19

Immune defense mechanisms in survivors of the COronaVIrus Disease-19 (COVID-19) and development their rehabilitation during pandemic both portray a great scientific practical interest. The aim study was to explore effect Immunovac-VP-4® (I-VP-4), vaccine based on bacterial ligands, clinical airway mucosal immunity parameters, along with systemic immune response group medical workers post-COVID period persons who did not develop disease. Methods . 82 healthcare aged from 18 65 years were included prospective open controlled study. participants divided into 4 groups: groups 1 (n = 20) 2 27) those history COVID-19, 3 18) 17) have Volunteers received I-VP-4. Samples oral fluid, induced sputum, nasopharyngeal oropharyngeal mucosa scrapings, venous blood examined. levels total secretory immunoglobulin class A (sIgA) G (IgG) determined by enzyme immunoassay. phagocytic index (PI) leukocytes assessed flow cytometry. Results patients COVID-19 IVP-4 (Group 3) showed tendency smaller number cases, as well some reduction days incapacity for work due acute respiratory infections (ARI). improved parameters innate response. sIgA increased sputum (p < 0.005) unchanged samples Group 1. PI macrophages fluid doubled 0.05) this group. At same time, decreased 2. In non-infected vaccinated 3), significant increase monocytes found day 90 0.05). Also, four-fold comparison noted. Conclusion I-VP-4 can be recommended programs prevention ARIs.